Weiss, HA; Paz Bailey, G; Phiri, S; Gresenguet, G; Legoff, J; Pepin, J; Lewis, DA; Belec, L; Hoffman, IF; Miller, WC; Mayaud, P (2011) Episodic therapy for genital herpes in sub-saharan Africa: a pooled analysis from three randomized controlled trials. PLoS One, 6 (7). e22601. ISSN 1932-6203 DOI: 10.1371/journal.pone.0022601

Downloaded from: http://researchonline.lshtm.ac.uk/325/

DOI: 10.1371/journal.pone.0022601

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Episodic Therapy for Genital Herpes in Sub-Saharan Africa: A Pooled Analysis from Three Randomized Controlled Trials

Helen A. Weiss1*, Gabriela Paz Bailey2, Sam Phiri3, Gerard Gresenguet4, Jerome LeGoff5, Jacques Pepin6, David A. Lewis1,7,8, Laurent Belec5, Irving F. Hoffman9, William C. Miller9, Philippe Mayaud1

1London School of Hygiene and Tropical Medicine, London, United Kingdom, 2Del Valle University of Guatemala, Guatemala and Tephinet Inc, Decatur, Guatemala, 3Lighthouse Trust, Lilongwe, Malawi, 4Centre National de Référence pour les Maladies Sexuellement Transmissibles, Bangui, Central African Republic, 5Paris Diderot University and Laboratoire de Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France, 6Université de Sherbrooke, Sherbrooke, Canada, 7National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa, 8University of the Witwatersrand, Johannesburg, South Africa, 9University of North Carolina, Chapel Hill, North Carolina, United States of America

Abstract

Background: A randomized controlled trial in South Africa found a beneficial effect of acyclovir on genital ulcer healing, but no effect was seen in trials in Ghana, Central African Republic and Malawi. The aim of this paper is to assess whether the variation in impact of acyclovir on ulcer healing in these trials can be explained by differences in the characteristics of the study populations.

Methodology/Principal Findings: Pooled data were analysed to estimate the impact of acyclovir on the proportion of ulcers healed seven days after randomisation by HIV/CD4 status, ulcer aetiology, size and duration before presentation; and impact on lesional HIV-1. Risk ratios (RR) were estimated using Poisson regression with robust standard errors. Of 1478 patients with genital ulcer, most (63%) had herpetic ulcers (16% first episode HSV-2 ulcers), and a further 3% chancreoid, 2% syphilis, 0.7% lymphogranuloma venereum and 31% undetermined aetiology. Over half (58%) of patients were HIV-1 seropositive. The median duration of symptoms before presentation was 6 days. Patients on acyclovir were more likely to have a healed ulcer on day 7 (63% vs 57%, RR = 1.08, 95% CI 0.98–1.18), shorter time to healing (p = 0.04) and less lesional HIV-1 RNA (p = 0.03). Small ulcers (<50 mm²), HSV-2 ulcers, first episode HSV-2 ulcers, and ulcers in HIV-1 seropositive individuals responded best but the better effectiveness in South Africa was not explained by differences in these factors.

Conclusions/Significance: There may be slight benefit in adding acyclovir to syndromic management in settings where most ulcers are genital herpes. The stronger effect among HIV-1 infected individuals suggests that acyclovir may be beneficial for GUD/HIV-1 co-infected patients. The high prevalence in this population highlights that genital ulceration in patients with unknown HIV status provides a potential entry point for provider-initiated HIV testing.

Introduction

Herpes simplex virus-2 (HSV-2) is the most common cause of genital ulcer disease (GUD) worldwide [1]. The natural course of genital herpes consists of subclinical genital viral shedding and clinical recurrences of blisters and ulcers which occur on the vulva, vagina or cervix in women, and on the glans, prepuce or shaft of the penis in men. The first episode of genital herpes is usually the most severe, lasting 2 to 4 weeks if untreated, and subsequent recurrences last 7 to 12 days without treatment [2]. A study conducted in the 1980s reported that oral acyclovir significantly reduced viral shedding, improved ulcer healing and decreased the incidence of new lesion formation among patients with recurrent genital herpes who received treatment within 48 hours of the onset of lesions [3]. A similar effect was seen on first episode genital herpes [4]. In 2003, the World Health Organization (WHO) published sexually transmitted infections (STI) treatment guidelines recommending addition of acyclovir to syndromic management of GUD in countries where the prevalence of HSV-2 as a GUD aetiology exceeds 30% [5]. However, a recent survey conducted in eight African countries found that acyclovir was rarely available in public health facilities, mainly due to cost and regulatory barriers [6].

The effectiveness of adding acyclovir to syndromic management for GUD in Africa was recently evaluated in three randomized controlled trials (RCTs). Two of the trials, one among women in...
Ghana and Central African Republic (CAR) and one among both men and women in Malawi, found no impact of standard dose acyclovir on ulcer healing [7–8]. However, a trial among South African men found that healing was significantly faster among those in the acyclovir arm (61% vs 42% healed at day 7; \( p = 0.003 \)) [9] and acyclovir is now included in the guidelines for first-line management of GUD in South Africa [10].

In this paper, we analyze pooled data from the three RCTs to assess whether the variation in impact of acyclovir on ulcer healing can be explained by differences in the characteristics of the study populations in this large series of patients presenting with GUD in four distinct African settings.

Methods

Details of the three individual trials have been reported elsewhere [7–9] (Trials registration numbers: NCT00158483, ISRCTN32121857, NCT00164424). The trials had similar designs, with an a-priori plan to conduct pooled analyses. Briefly, in each trial, consenting consecutive patients with clinically confirmed GUD were enrolled and randomized to either acyclovir or placebo (400 mg three times daily for 5 days for Ghana/CAR and South Africa; 800 mg two times daily for 5 days in Malawi). Patients with very large ulcers (surface area \( \geq 500 \text{ mm}^2 \)) and those with long ulcer duration (\( \geq 21 \text{ days} \)) were not included in the trial in Ghana/CAR and were treated immediately with acyclovir instead. Participants were asked to return for follow-up on day 2 and/or 4, day 7, day 10 (South Africa only), day 14 and day 28.

The primary outcomes in this analysis were the impact of acyclovir on the proportion of ulcers healed and lesional HIV-1 RNA (in HIV-1 seropositive patients) at 7 days post-randomization (defined as visits occurring on days 6–8 inclusive). The secondary outcome was time to ulcer healing over the 28 days of follow-up.

Ulcer healing was defined as a reduction in the size (in \( \text{mm}^2 \)) of the largest ulcer at baseline by at least 90%. Further analyses used absolute ulcer size (<10 mm\(^2\)) as the outcome. Thresholds for detectable lesional HIV-1 RNA were 50 copies/mL for South Africa, 250 copies/mL for Ghana/CAR, and 400 copies/mL for Malawi. Ulcers which were not sampled because they were healed were assumed to have undetectable lesional HIV-1 RNA.

Sub-groups of interest were defined a-priori as follows:

i) Ulcer aetiology (HSV ulcer, non-HSV ulcer, first episode HSV-2 ulcer, recurrent HSV-2 ulcer). First episode HSV-2 ulcers are defined as HSV-2 seronegative patients with HSV-2 DNA detected in the lesion. Six patients who had an HSV-1 ulcer without evidence of lesional HSV-2 infection were included as HSV ulcers.

ii) Duration of symptoms before presentation (\( \leq 2 \text{ days}, 3–4 \text{ days}, 5–6 \text{ days}, > 7 \text{ days} \)).

iii) Size of ulcer at baseline (<50 mm\(^2\), \( \geq 50 \text{ mm}^2 \)).

iv) HIV/CD4 status: HIV seronegative, HIV-1 seropositive with CD4 \( > 500 \text{ cells/mm}^2 \); HIV-1 seropositive with CD4 200–500 cells/mm\(^2\); HIV-1 seropositive with CD4 \(< 200 \text{ cells/mm}^2\). Too few patients were on antiretroviral therapy to analyse these separately.

Statistical analyses were conducted in Stata 11.0 (StataCorp, Texas, USA). Poisson regression with robust standard errors was used to estimate risk ratios (RR) and 95% confidence intervals (CI) [11]. The risk difference and 95% CI for the primary analysis was also estimated, using binominal methods. Time-to-ulcer-healing was assessed graphically using Kaplan-Meier analysis and a log-rank test was used to obtain a p-value for a difference in time-to-healing by arm. The Kruskal-Wallis test was used to compare median durations between study sites. To investigate whether the differential effect of acyclovir in South Africa could be explained by factors associated with ulcer healing, we stratified analyses by South Africa versus non South Africa sites and tested for effect-modification by site. To allow for imbalances between arms, risk ratios of the impact of acyclovir were adjusted for factors potentially associated with ulcer healing (ulcer aetiology, size, duration of symptoms before enrolment and HIV status).

Ethics statement

Each trial was approved by the ethics committee of the London School of Hygiene and Tropical Medicine, and the following local ethics committees and institutional review boards: ANRS 1212 - ethics committees of the Ministries of Health of Ghana and the Central African Republic; Malawi trial - National Health Sciences Research Committee in Malawi and the ethics committees of University of North Carolina and the US Centers for Disease Control and Prevention (CDC); South Africa - ethics committees and institutional review boards of the University of the Witwatersrand, the CDC, and the Gauteng Provincial and City of Johannesburg Health Departments. All participants provided written informed consent.

Results

Characteristics of GUD patients

Of the 1516 GUD patients eligible for the three trials, 1478 were randomized (550 female and 928 male). The flow of participants through the trials is shown in Figure 1. Socio-demographic and behavioural characteristics of the participants are shown in Table 1 (by trial arm) and Table 2 (by site). There was good balance in characteristics by trial arm (Table 1). The median age of participants was 28 years (interquartile range 24–34 years), and this was similar by study site and sex. Overall, almost half of men (47%) and one-third of women (33%) reported having had a previous GUD in the past year (Table 2). At the enrolment visit, the median number of ulcers per patient was two in each country, and women in Ghana and CAR tended to have fewer ulcers than patients in Malawi and South Africa. The size of the largest ulcer was measured for each patient, and varied considerably, with median size being smallest in Malawi (21 mm\(^2\) and 28 mm\(^2\) respectively in women and men), and largest in Ghana and CAR (147 mm\(^2\) and 130 mm\(^2\), respectively), despite exclusion of ulcers \( \geq 500 \text{ mm}^2 \) in these sites. The median time from first symptoms to presentation was 6 days, and this was slightly shorter in South Africa and Ghana (5 days) than among women in CAR and women in Malawi (7 days; \( p = 0.0001 \)). Overall, 28% of women and 13% of men were on antibiotics for the current ulcer, including 43% of women in CAR.

HIV-1 seroprevalence was high in all sites, ranging from 34% among women in Ghana to 77% among Malawian women (Table 3). Among HIV-1 infected persons, mean HIV-1 plasma viral load was 4.77 log_{10} copies/mL (95% CI 4.71–4.84) overall, but varied significantly between site (\( p < 0.0001 \)), being lowest in Ghana (4.26 log_{10} copies/mL), where the proportion of participants with CD4 count above 500 cells/mm\(^2\) was also highest (38%). Overall, almost half of HIV-1 seropositive women (47%), and a third of HIV-1 seropositive men (34%) presented with CD4 counts below 200 cells/mm\(^2\). Despite this, the proportion of HIV-1 seropositive participants on antiretroviral therapy was low (9% in women, 3% in men). Overall, about half of the HIV-1 seropositive participants had detectable lesional HIV-1 RNA at
enrollment, but this varied substantially by site (from 31% among women in Malawi to 80% in CAR; \( p < 0.0001 \)).

HSV-2 seroprevalence was 74% overall, and varied significantly by site, being highest among women in CAR (95%) and Malawi (81%) compared to women in Ghana and men in Malawi and South Africa (69–71%) (\( p < 0.0001 \)). Overall, about two-thirds of ulcers had detectable HSV DNA (type 1 or 2) alone or in combination with other pathogens, making this the most common ulcer aetiology (Figure 2). Of the 930 HSV ulcers, 6 had detectable HSV-1 DNA only (one from Ghana, 5 from South Africa), and the remaining 924 had detectable HSV-2 DNA. Of these, 225 (24%) ulcers were first episode HSV-2 ulcers, 693 (76%) had recurrent HSV-2 ulcers and the remaining 6 had unknown HSV-2 serostatus. A total of 154 participants (10.4%) had at least one lesional bacterial infection detected, and 90 participants (6.1%) had bacterial infections only. Prevalence of chancroid was 4.9% (\( n = 73 \)), syphilis 3.5% (\( n = 52 \)), and lymphogranuloma venereum 2.2% (\( n = 33 \)), whilst 435 ulcers (30%) had undefined or unknown aetiology.

Impact of acyclovir on ulcer healing

Of the 1478 patients enrolled, 1258 (85%) were seen on day 7, of whom 1255 had a genital examination (Figure 1). The proportion seen was similar by site (ranging from 82% among Malawian women to 89% in women in CAR) and by arm (85% in each arm).

Overall, there was a small impact of acyclovir on the proportion of ulcers healed on day 7 (63% vs. 57% in acyclovir and placebo arms respectively; \( RR = 1.10 \), 95% CI 1.00–1.20; risk difference = 5.7%, 95% CI 0.3%–11.1%; Table 4). Adjustment for factors potentially associated with ulcer healing rate (GUD aetiology, size of ulcer at baseline, duration before presentation, and HIV/CD4

---

Figure 1. CONSORT flow diagram of eligibility, enrolment and follow-up in three African randomized controlled trials of episodic therapy for genital herpes.
doi:10.1371/journal.pone.0022601.g001
The impact on healing was greatest in South Africa (aRR = 1.30, 95% CI 1.09–1.55; other sites: aRR = 1.02, 95% CI 0.90–1.14). However, the effect on healing of HSV ulcers was seen only in South Africa (South Africa: aRR = 1.30, 95% CI 1.09–1.55; other sites: aRR = 1.03, 95% CI 0.89–1.20; p-interaction = 0.05). The impact was strongest for first episode HSV-2 ulcers (aRR = 1.26, 95% CI 1.00–1.57), and again the effect was limited to South Africa (South Africa: aRR = 1.43, 95% CI 0.98–2.09; other sites: aRR = 1.07, 95% CI 0.83–1.37; p-interaction = 0.12).

There was little difference in impact of acyclovir by duration of symptoms before presentation, but acyclovir had a better impact on healing of small ulcers than larger ulcers (p-interaction = 0.002; Table 4). Again, differences persisted between South African and the other sites (aRR for small ulcers in South Africa = 1.33, 95% CI 1.13–1.55; aRR for small ulcers in other sites = 1.10, 95% CI 0.95–1.26; p-interaction = 0.09).

The effect of acyclovir was slightly stronger among HIV-1 seropositive individuals (aRR = 1.16, 95% CI 1.01–1.32; Table 4) than HIV-uninfected individuals (aRR = 1.02, 95% CI 0.90–1.14). The effect among HIV-1 seropositive individuals was largely due to an effect in South Africa (aRR = 1.31, 95% CI 1.06–1.60) rather than in other sites (aRR = 1.08, 95% CI 0.90–1.30), although this difference was not significant (p-interaction = 0.17). A similar pattern was seen when analyses were restricted to HIV-1 seropositive individuals with HSV-2 ulcers (Figure 3c and 3d). In this subgroup, there was evidence of an impact overall (aRR = 1.20, 95% CI 1.02–1.41) but this was only seen in South Africa (aRR = 1.46, 95% CI 1.16–1.85) and not in other sites (aRR = 0.98, 95% CI 0.78–1.2; p-interaction = 0.03).

Impact of acyclovir on lesional HIV-1 RNA

Of the 726 HIV-1 seropositive individuals who were seen on Day 7, data on lesional HIV-1 RNA was available for 667 (92%) (Table 5). Overall, there was evidence of an impact of the intervention on detectable lesional HIV-1 RNA after adjusting for ulcer aetiology, size of ulcers, duration of symptoms and CD4 group (aRR = 0.73, 95%CI:0.55–0.98). Again, the impact was confined to South Africa (aRR = 0.58, 95% CI 0.39–0.84), with no evidence of an effect at other sites (aRR = 1.01, 95% CI 0.65–1.57; p-interaction = 0.05; results not shown).

Among the 466 HIV-1 seropositive individuals with HSV ulcers, there was strong evidence of an effect on the intervention on reducing prevalence of detectable lesional HIV-1 RNA (aRR = 0.66, 95% CI 0.47–0.92) and this was greater among the 64 participants with first episode HSV-2 ulcers (aRR = 0.20, 95% CI 0.03–1.11) compared to the effect among the 401 participants with recurrent HSV-2 ulcers (aRR = 0.74, 95% CI 0.52–1.02), although this difference was not significant (p-interaction = 0.13). The impact on both types of HSV-2 ulcers was stronger in South Africa, although the differences were not significant.

The impact on lesional HIV-1 RNA was also stronger in those presenting within a week of symptoms (RR = 0.54, 95% CI 0.33–0.90) and those with small ulcers (RR = 0.55, 95% CI 0.31–0.87). Overall, there was no evidence of an impact among the patients with CD4 counts above 500 cells/mm³ or below 200 cells/mm³.
Table 2. Demographic, behavioural and clinic characteristics of 1478 trial participants with genital ulcer disease (GUD) at enrolment, by country and sex.

|                      | Ghana Females | CAR Females | Malawi Females | Malawi Males | S Africa Males | All females | All males |
|----------------------|---------------|-------------|----------------|--------------|----------------|-------------|-----------|
| Total                | N = 284       | N = 157     | N = 109        | N = 313      | N = 615        | N = 550     | N = 928   |
| Age, years           |               |             |                |              |                |             |           |
| 15–24                | 110 (39%)     | 48 (31%)    | 40 (37%)       | 73 (23%)     | 130 (21%)      | 198 (36%)   | 203 (22%) |
| 25–34                | 104 (37%)     | 75 (48%)    | 48 (44%)       | 186 (59%)    | 323 (53%)      | 227 (41%)   | 509 (55%) |
| > = 35               | 68 (24%)      | 34 (22%)    | 21 (19%)       | 54 (17%)     | 162 (26%)      | 123 (22%)   | 216 (23%) |
| Median (IQR\(^{a}\)) | 27 (23–34)    | 29 (23–34)  | 28 (23–33)     | 28 (25–33)   | 29 (25–35)     | 28 (23–34)  | 29 (25–34) |
| Marital status       |               |             |                |              |                |             |           |
| Single               | 163 (58%)     | 52 (33%)    | 16 (15%)       | 115 (37%)    | 354 (58%)      | 231 (42%)   | 469 (51%) |
| Married              | 72 (26%)      | 60 (38%)    | 62 (57%)       | 164 (52%)    | 239 (39%)      | 194 (35%)   | 403 (43%) |
| Sep/div/widow        | 47 (17%)      | 45 (29%)    | 31 (28%)       | 34 (11%)     | 22 (4%)        | 123 (22%)   | 56 (6%)   |
| Education            |               |             |                |              |                |             |           |
| Primary or lower     | 131 (47%)     | 76 (48%)    | 59 (54%)       | 160 (51%)    | 137 (22%)      | 266 (49%)   | 297 (32%) |
| Secondary or higher  | 150 (53%)     | 81 (52%)    | 50 (46%)       | 153 (49%)    | 477 (78%)      | 281 (51%)   | 630 (68%) |
| Number of partners in last 3 months |             |             |                |              |                |             |           |
| None                 | 99 (35%)      | 130 (83%)   | 14 (13%)       | 20 (6%)      | 46 (8%)        | 243 (44%)   | 66 (47%)  |
| 1                    | 107 (38%)     | 22 (14%)    | 75 (69%)       | 185 (59%)    | 381 (62%)      | 204 (37%)   | 566 (61%) |
| 2–9                  | 22 (8%)       | 3 (2%)      | 19 (17%)       | 108 (35%)    | 180 (30%)      | 44 (8%)     | 288 (31%) |
| >=10                 | 54 (19%)      | 2 (1%)      | 0 (0%)         | 3 (0.5%)     | 56 (11%)       | 3 (<1%)     |           |
| New partner in last 3 months\(^{b}\) | 79 (28%) | 10 (6%) | 21 (19%) | 158 (50%) | n/a | 110 (20%) | 158 (50%) |
| Sex for money/gifts  | 59 (21%)      | 8 (5%)      | 21 (19%)       | 79 (13%)     | 88 (16%)       | 198 (21%)   |           |
| Reported GUD in past year | 79 (28%) | 63 (40%) | 40 (37%) | 117 (37%) | 308 (52%) | 186 (33%) | 425 (47%) |
| Number of ulcers     |               |             |                |              |                |             |           |
| 1                    | 117 (42%)     | 70 (45%)    | 31 (28%)       | 100 (32%)    | 214 (36%)      | 218 (40%)   | 314 (35%) |
| 2                    | 79 (28%)      | 45 (29%)    | 26 (24%)       | 58 (19%)     | 114 (19%)      | 150 (28%)   | 172 (19%) |
| 3                    | 54 (19%)      | 21 (13%)    | 16 (15%)       | 44 (14%)     | 77 (13%)       | 91 (17%)    | 121 (13%) |
| >=4                  | 28 (10%)      | 21 (13%)    | 36 (33%)       | 111 (35%)    | 192 (33%)      | 85 (16%)    | 303 (33%) |
| Median (IQR)         | 2 (1–3)       | 2 (1–3)     | 2 (1–4)        | 2 (1–5)      | 2 (1–4)        | 2 (1–3)     | 2 (1–4)   |
| Size of largest ulcer, mm\(^2\) |             |             |                |              |                |             |           |
| <50                  | 101 (36%)     | 18 (11%)    | 72 (66%)       | 200 (64%)    | 394 (64%)      | 191 (35%)   | 594 (64%) |
| 50–149               | 50 (18%)      | 80 (51%)    | 30 (28%)       | 76 (24%)     | 143 (23%)      | 160 (29%)   | 219 (24%) |
| 150–299              | 69 (24%)      | 48 (31%)    | 6 (6%)         | 22 (7%)      | 55 (9%)        | 123 (22%)   | 77 (8%)   |
| 300–500              | 62 (22%)      | 11 (7%)     | 1 (1%)         | 11 (4%)      | 21 (3%)        | 74 (14%)    | 32 (3%)   |
| Median (IQR)         | 147 (30–290)  | 130 (80–195)| 21 (12–50)    | 28 (12–75)   | 35 (15–81)     | 100 (28–221)| 32 (15–79)|
| Duration of symptoms at presentation |         |             |                |              |                |             |           |
| 1–2 days             | 22 (8%)       | 3 (2%)      | 5 (5%)         | 17 (5%)      | 49 (8%)        | 30 (6%)     | 66 (7%)   |
| 3–6 days             | 145 (52%)     | 46 (30%)    | 43 (42%)       | 141 (45%)    | 289 (48%)      | 234 (44%)   | 430 (47%) |
| 1 week +             | 84 (30%)      | 45 (29%)    | 24 (23%)       | 67 (21%)     | 158 (26%)      | 153 (28%)   | 225 (25%) |
| 2 weeks +            | 20 (7%)       | 32 (21%)    | 15 (15%)       | 40 (13%)     | 79 (13%)       | 67 (12%)    | 119 (13%) |
| 3 weeks +            | 8 (3%)        | 29 (19%)    | 16 (16%)       | 48 (15%)     | 26 (4%)        | 53 (10%)    | 74 (8%)   |
| Median days (IQR)    | 5 (3–7)       | 7 (5–15)    | 7 (4–14)       | 6 (6–14)     | 5 (3–8)        | 7 (4–10)    | 6 (4–10)  |
| On antibiotics       | 60 (21%)      | 68 (43%)    | 24 (22%)       | 68 (22%)     | 55 (9%)        | 152 (28%)   | 123 (13%) |

\(^{a}\)Interquartile range.

\(^{b}\)This question was not asked in the South African trial.

\(^{c}\)For Ghana and CAR, this is current occupation as a sexworker. In Malawi and South Africa, the question refers to ever having exchanged sex for money.

doi:10.1371/journal.pone.0022601.t002
Table 3. HIV/HSV-related characteristics of trial participants with genital ulcer disease (GUD) at enrolment, by country & sex.

|                      | Ghana Females | CAR Females | Malawi Females | Malawi Males | S Africa Males | All females | All males |
|----------------------|---------------|-------------|----------------|--------------|----------------|-------------|-----------|
|                      | N = 284       | N = 157     | N = 109        | N = 313      | N = 615        | N = 550     | N = 928   |
| HIV-1 seropositive   | n (%)         | n (%)       | n (%)          | n (%)        | n (%)          | n (%)       | n (%)     |
| Mean plasma viral load, log_{10} copies/mL (95%CI) | 4.26 (4.01–4.51) | 4.95 (4.71–5.19) | 4.74 (4.55–4.93) | 4.90 (4.78–5.02) | 4.80 (4.72–4.88) | 4.66 (4.53–4.80) | 4.83 (4.77–4.90) |
| CD4 count^{a,b,1} cells/mm^3 |                          |                          |                |              |                |                          |            |
| >500                 | 28 (38%)      | 10 (24%)    | 6 (8%)         | 23 (15%)     | 59 (15%)       | 44 (23%)    | 82 (15%)  |
| 200–500              | 19 (26%)      | 10 (24%)    | 27 (36%)       | 80 (51%)     | 196 (51%)      | 56 (29%)    | 276 (51%) |
| <200                 | 26 (36%)      | 22 (52%)    | 42 (56%)       | 54 (34%)     | 130 (34%)      | 90 (47%)    | 184 (34%) |
| Median CD4 (IQR)     | 361 (138–611) | 193 (70–479) | 173 (84–347)  | 263 (151–409)| 282 (165–419) | 223 (104–467)| 279 (164–417)|
| On antiretrovirals^{a,c} | 7 (7%)        | 12 (11%)    | 7 (8%)         | 5 (3%)       | 9 (3%)         | 26 (9%)     | 14 (3%)   |
| Detectable lesional HIV-1 RNA^{a,c,d} | 11/31 (35%) | 84/105 (80%) | 24/78 (31%) | 82/164 (50%) | 173/379 (46%) | 119/214 (56%) | 255/543 (47%) |
| HSV-2 seropositive   | 198 (71%)     | 149 (95%)   | 85 (81%)       | 214 (69%)    | 434 (71%)      | 430 (79%)   | 648 (70%) |
| HSV ulcer (HSV-1 or HSV-2) | 120 (45%)     | 92 (59%)    | 83 (76%)       | 184 (59%)    | 451 (74%)      | 295 (56%)   | 635 (69%) |
| HSV-2 ulcer          | 119 (45%)     | 92 (59%)    | 83 (76%)       | 184 (59%)    | 446 (73%)      | 294 (55%)   | 630 (58%) |
| First episode HSV-2 ulcer^{e} | 19 (7%)         | 5 (3%)      | 10 (9%)        | 57 (18%)     | 134 (22%)      | 34 (6%)     | 191 (21%) |
| HIV-1 seropositive with HSV-2 ulcer | 52 (19%)         | 64 (41%)    | 67 (61%)       | 112 (36%)    | 293 (48%)      | 183 (34%)   | 405 (44%) |
| Detectable lesional HIV-1 RNA in HIV-1 seropositive patients with HSV-2 ulcers^{f} | 9 (47%)        | 53 (84%)    | 21 (33%)       | 48 (44%)     | 120 (42%)      | 83 (57%)    | 168 (43%) |

^{a}Among HIV seropositive individuals.
^{b}Missing CD4 data for 22/95 HIV positive women in Ghana; 86/108 in CAR; 9/84 women in Malawi; 16/173 men in Malawi, 2/387 men in South Africa.
^{c}Missing ARV data for 1/95 women in Ghana and 54/387 men in South Africa.
^{d}Uses threshold of: 250 copies/mL for Ghana & CAR; 400 copies/mL for Malawi; 50 copies/mL for S Africa. Lesional HIV-1 RNA only.
^{e}Defined as HSV-2 seronegative and HSV-2 DNA detected in the ulcer. Data are missing for 27 participants (21 with missing ulcer aetiology, 6 with missing HSV-2 serostatus).
^{f}Among 541 HIV-1 seropositive individuals with HSV-2 ulcers and data on lesional HIV-1 RNA.

doi:10.1371/journal.pone.0022601.t003

Figure 2. Ulcer aetiology in genital ulcer disease patients in Sub-Saharan African trials, by country and sex.
doi:10.1371/journal.pone.0022601.g002
but strong evidence of reduced lesional HIV-1 RNA associated with acyclovir among those with CD4 counts between 200 and 500 cells/mm$^3$ (adjusted RR = 0.48, 95% CI 0.29–0.80). There was no evidence of interaction by site, but in the South African patients, there was a protective effect of acyclovir in each CD4 group (CD4 $\geq 500$ cells/mm$^3$: RR = 0.69, 95% CI 0.11–4.31; CD4 200–500 cells/mm$^3$: RR = 0.34, 95% CI 0.17–0.68; CD4<200 cells/mm$^3$: RR = 0.84, 95% CI 0.53–1.32). By contrast, little effect was observed in the non-South African patients (CD4 $\geq 500$ cells/mm$^3$: RR = 3.47, 95% CI 0.33–36.36; CD4 200–500 cells/mm$^3$: RR = 0.74, 95% CI 0.35–1.57; CD4<200 cells/mm$^3$: RR = 0.87; 95% CI 0.48–1.55).

### Discussion

Herpes simplex virus type 2 is a recognised and important cofactor of the HIV epidemic [1,12–14]. A number of RCTs have failed to demonstrate an impact of HSV suppressive treatment on acquisition [15–16] or transmission [17] of HIV, although acyclovir or valacyclovir have been shown to decrease plasma and genital HIV levels [18–24] and even to modestly reduce HIV disease progression [25]. A meta-analysis of 8 RCTs showed that high dose acyclovir ($\geq 3200$ mg/day) significantly reduced mortality among HIV-infected individuals [26]. In this pooled analysis of episodic therapy trials, there was a small impact of acyclovir on the proportion of ulcers healed on day 7 and this was more substantial among patients with HSV ulcers, first episode HSV-2 ulcers, small ulcers, and HIV-1 seropositive individuals with CD4 counts between 200 and 500 cells/mm$^2$. However, the impact was consistently greater in South Africa than in other sites, and this was not explained by different distributions of these clinical characteristics.

It is challenging to explain the greater impact of acyclovir on ulcer healing and lesional HIV in South Africa compared with other sites. The acyclovir regimen was the same in South Africa as in Ghana and Central African Republic (400 mg three times daily

### Table 4. Impact of acyclovir on ulcer healing$^1$ at Day 7 among 1255 trial participants.

|                      | Total N = 628 | Placebo n (% healed) | Acyclovir n (% healed) | Risk ratio (95% CI) | Adjusted risk ratio (95% CI)$^2$
|----------------------|--------------|----------------------|------------------------|---------------------|-----------------------------|
|                      | N = 627      |                      |                        |                     |                             |
| All patients         | 1255         | 358 (57%)            | 393 (63%)              | 1.10 (1.00–1.20)    | 1.08 (0.98–1.18)            |
| Country and sex      |              |                      |                        |                     |                             |
| Ghana Females        | 243          | 99 (81%)             | 97 (80%)               | 0.99 (0.87–1.12)    | 1.00 (0.88–1.14)            |
| CAR Females          | 139          | 25 (34%)             | 23 (35%)               | 1.02 (0.64–1.61)    | 0.80 (0.43–1.48)            |
| Malawi Females       | 88           | 30 (70%)             | 32 (70%)               | 1.01 (0.76–1.31)    | 1.00 (0.73–1.35)            |
| Malawi Males         | 273          | 72 (53%)             | 73 (54%)               | 1.02 (0.82–1.28)    | 0.99 (0.80–1.23)            |
| South Africa Males   | 512          | 133 (52%)            | 168 (65%)              | 1.24 (1.07–1.44)    | 1.21 (1.05–1.40)            |
| By ulcer aetiology at presentation |            |                      |                        |                     |                             |
| Non HSV ulcer        | 450          | 135 (62%)            | 141 (61%)              | 0.98 (0.84–1.13)    | 0.94 (0.81–1.09)            |
| HSV ulcer            | 788          | 212 (53%)            | 246 (63%)              | 1.19 (1.06–1.34)    | 1.15 (1.03–1.29)            |
| First episode HSV-2 ulcer | 188   | 54 (26%)             | 61 (68%)               | 1.22 (0.98–1.54)    | 1.26 (1.00–1.57)            |
| Recurrent HSV-2 ulcer | 593         | 156 (52%)            | 183 (62%)              | 1.18 (1.03–1.36)    | 1.14 (1.00–1.30)            |
| HSV-2 ulcer only     | 736          | 201 (53%)            | 231 (64%)              | 1.21 (1.07–1.36)    | 1.17 (1.04–1.32)            |
| HSV-2 plus bacterial infection | 46    | 11 (55%)             | 15 (58%)               | 1.05 (0.62–1.77)    | 0.94 (0.57–1.55)            |
| By duration before presentation |            |                      |                        |                     |                             |
| 1–2 days             | 78           | 26 (72%)             | 30 (71%)               | 0.99 (0.75–1.31)    | 1.09 (0.85–1.40)            |
| 3–4 days             | 360          | 115 (64%)            | 132 (73%)              | 1.15 (1.00–1.32)    | 1.11 (0.97–1.28)            |
| 5–6 days             | 209          | 69 (63%)             | 61 (62%)               | 0.98 (0.79–1.21)    | 0.93 (0.75–1.15)            |
| $\geq$ 7 days        | 587          | 141 (48%)            | 160 (54%)              | 1.13 (0.97–1.33)    | 1.14 (0.97–1.34)            |
| By size of ulcer at baseline |        |                      |                        |                     |                             |
| $<50$ mm$^2$         | 663          | 196 (60%)            | 253 (74%)              | 1.23 (1.11–1.37)    | 1.20 (1.08–1.34)            |
| $\geq 50$ mm$^2$     | 590          | 162 (53%)            | 140 (49%)              | 0.91 (0.78–1.07)    | 0.88 (0.74–1.03)            |
| By HIV/CD4 status (cells/mm$^3$)$^3$ |      |                      |                        |                     |                             |
| HIV uninfected       | 524          | 174 (69%)            | 188 (70%)              | 1.02 (0.91–1.14)    | 1.02 (0.90–1.14)            |
| HIV-1 infected       | 726          | 182 (49%)            | 202 (57%)              | 1.16 (1.02–1.33)    | 1.16 (1.01–1.32)            |
| HIV-1 infected, CD4<500 | 101      | 33 (60%)             | 27 (59%)               | 0.98 (0.71–1.36)    | 0.99 (0.74–1.31)            |
| HIV-1 infected, CD4 200–500 | 275    | 64 (49%)             | 91 (63%)               | 1.29 (1.04–1.60)    | 1.25 (1.02–1.53)            |
| HIV-1 infected, CD4<200 | 249      | 64 (50%)             | 62 (52%)               | 1.03 (0.81–1.32)    | 1.00 (0.79–1.27)            |

$^1$Defined as a $\geq 90\%$ reduction in size of largest ulcer from enrolment.

$^2$Risk ratio for impact of acyclovir among people in that strata, adjusted for all other variables in the table (ulcer aetiology is categorised as non-HSV ulcer, HSV ulcer).

$^3$P-value for interaction.

$^4$Interaction between non-HSV and HSV ulcers.

10.1371/journal.pone.0022601.t004

doi:10.1371/journal.pone.0022601.t004
Episodic Therapy for Herpes in Africa

Almost two-thirds of ulcers were due to HSV-2, and of these, a quarter (225/918), were first-episode HSV-2 ulcers, representing also 16% of all GUD. Only 10% of all ulcers had a bacterial aetiology, alone or combined with HSV, although this varied by country. HIV-1 prevalence was high in these populations (58%), and a large proportion had CD4 counts below 200 cells/mm³, while few individuals were on antiretroviral therapy at the time of enrolment in 2003–2006.

The three trials were pragmatic trials designed to evaluate the effectiveness of adding acyclovir to current syndromic management of GUD, rather than the efficacy of acyclovir on treating herpetic ulcers per se. Although it is clear that there was a benefit in South Africa, the overall results suggest that there may be limited value in adding acyclovir to GUD syndromic management in some other African settings. Approximately seventeen GUD patients would need to be treated with acyclovir for one additional patient to be healed on day 7. There is likely to be some benefit in settings where a high proportion of ulcers are genital herpes, especially first episode HSV-2 ulcers which responded best to treatment, but this clinical and lab-based information is rarely available in resource-poor settings. The stronger effect among HIV-1 infected individuals than HIV uninfected individuals overall also suggests that acyclovir may be beneficial for GUD patients known to be HIV-infected at the time of presentation to clinical services. The high prevalence in this population highlights that genital ulceration in patient with unknown HIV status provides a potential entry point for provider-initiated HIV testing and care.
It is not possible to diagnose HSV infection easily, quickly and cheaply, let alone primary HSV-2 ulcers, with current tools in resource-constrained clinical settings. Given the limited effectiveness of adding acyclovir to syndromic management overall, and the lack of clear reasons for why the regimen was more effective in one trial than the other two, further research is needed to explore better options for the management of GUD patients in sub-Saharan Africa.

Table 5. Impact of acyclovir on lesional HIV-1 RNA on Day 7 among 667 HIV-1 seropositive trial participants.

| Total | Placebo (% lesional HIV) | Acyclovir (% lesional HIV) | Risk ratio (95% CI) | Adjusted risk ratio1 (95% CI) |
|-------|--------------------------|---------------------------|---------------------|-------------------------------|
| **All patients** | 667 | 89 (27%) | 63 (19%) | 0.71 (0.53–0.94) | 0.73 (0.55–0.98) |
| **Country** | | | | P-int = 0.50 | P-int = 0.26 |
| Ghana Females | 70 | 1 (3%) | 1 (3%) | | |
| CAR Females | 94 | 21 (39%) | 15 (38%) | 0.96 (0.57–1.63) | 0.87 (0.48–1.59) |
| Malawi Females | 58 | 2 (8%) | 2 (6%) | | |
| Malawi Males | 135 | 16 (26%) | 17 (23%) | 0.90 (0.50–1.64) | 1.00 (0.54–1.83) |
| South Africa Males | 310 | 59 (31%) | 28 (18%) | 0.58 (0.38–0.87) | 0.58 (0.39–0.84) |
| **By ulcer aetiology** | | | | P-int = 0.332 | P-int = 0.223 |
| Non HSV ulcer | 200 | 20 (21%) | 20 (19%) | 0.90 (0.51–1.56) | 0.96 (0.52–1.76) |
| HSV ulcer | 466 | 69 (29%) | 43 (19%) | 0.66 (0.47–0.92) | 0.66 (0.48–0.92) |
| HSV-2 ulcer | 465 | 68 (29%) | 43 (19%) | 0.66 (0.47–0.93) | 0.66 (0.48–0.92) |
| First episode HSV-2 ulcer | 64 | 9 (27%) | 2 (7%) | 0.24 (0.05–1.02) | 0.20 (0.03–1.11) |
| Recurrent HSV-2 ulcer | 401 | 59 (29%) | 41 (21%) | 0.73 (0.51–1.03) | 0.74 (0.52–1.02) |
| **By duration before presentation** | | | | P-int = 0.56 | P-int = 0.32 |
| <2 days | 33 | 3 (18%) | 1 (6%) | 0.35 (0.04–3.17) | 0 |
| 3–4 days | 167 | 16 (18%) | 9 (11%) | 0.61 (0.29–1.31) | 0.57 (0.26–1.24) |
| 5–6 days | 121 | 19 (30%) | 9 (16%) | 0.51 (0.25–1.05) | 0.44 (0.21–0.92) |
| ≥7 days | 337 | 51 (31%) | 44 (25%) | 0.82 (0.58–1.15) | 0.88 (0.63–1.23) |
| **By size of ulcer at baseline** | | | | P = 0.52 | P-int = 0.33 |
| <50 mm² | 364 | 33 (19%) | 22 (12%) | 0.64 (0.39–1.05) | 0.55 (0.32–0.93) |
| ≥50 mm² | 303 | 56 (36%) | 41 (28%) | 0.78 (0.56–1.09) | 0.79 (0.57–1.11) |
| **By CD4 status (cells/mm³)** | | | | P-int = 0.06 | P-int = 0.12 |
| CD4≥500 | 92 | 5 (10%) | 7 (16%) | 1.60 (0.54–4.69) | 1.38 (0.54–3.50) |
| CD4 200–500 | 257 | 34 (29%) | 18 (13%) | 0.46 (0.27–0.77) | 0.48 (0.29–0.80) |
| CD4<200 | 226 | 37 (32%) | 29 (27%) | 0.84 (0.56–1.27) | 0.87 (0.62–1.23) |

1Adjusted for all other variables in the table.
2Insufficient data to estimate risk ratio and 95% CI.
3Interaction between non-HSV and HSV ulcers.

doi:10.1371/journal.pone.0022601.t005

Author Contributions
Conceived and designed the experiments: HAW GBP SP GG JL JP DAL LB IH WCM PM. Performed the experiments: GBP SP GG LB PM. Analyzed the data: HAW GBP SP. Wrote the paper: HAW GBP SP JL JP DAL LB IH WCM PM.

References
1. Weiss H (2004) Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 11 Suppl 1: 24A–35A.
2. Corey L, Adams HG, Brown ZA, Holmes KK (1983) Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 98: 958–972.
3. Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, et al. (1984) Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 251: 2103–2107.
4. Mertz GJ, Critchlow CW, Benedetti J, Reichman RC, Dolin R, et al. (1984) Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 252: 1147–1151.
5. Organization WH (2003) Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization. ISBN 92 4 154626 3 ISBN 92 4 154626 3.

It is not possible to diagnose HSV infection easily, quickly and cheaply, let alone primary HSV-2 ulcers, with current tools in resource-constrained clinical settings. Given the limited effectiveness of adding acyclovir to syndromic management overall, and the lack of clear reasons for why the regimen was more effective in one trial than the other two, further research is needed to explore better options for the management of GUD patients in sub-Saharan Africa.
10. Lewis DA, Marumo E (2010) Revision of the national guideline for first-line comprehensive management and control of sexually transmitted infections: what’s new and why? SA Fam Pract 52: 20–24.
11. Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159: 702–706.
12. Celum C, Levine R, Weaver M, Wald A (2004) Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 82: 447–453.
13. Corey I (2007) Synergistic copathogens–HIV-1 and HSV-2. N Engl J Med 356: 834–836.
14. Glynn JR, Biraro S, Weiss HA (2009) Herpes simplex virus type 2: a key role in HIV incidence. AIDS 23: 1593–1598.
15. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, et al. (2008) Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 358: 1560–1571.
16. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371: 2109–2119.
17. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, et al. (2010) Aciclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 362: 427–439.
18. Dunne EF, Whitehead S, Sternberg M, Theramnuay S, Loeaswiwat W, et al. (2008) Suppressive aciclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 49: 77–83.
19. Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, et al. (2008) A randomised placebo-controlled trial to explore the effect of suppressive therapy with aciclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 84: 548–553.
20. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. (2007) Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 196: 1500–1508.
21. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. (2009) HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 23: 479–483.
22. Barton JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, et al. (2008) Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 co-infected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 198: 1084–1088.
23. Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, et al. (2010) Long-term impact of aciclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. J Infect Dis 201: 1205–1207.
24. Delany S, Mhla N, Clayton T, Akpounemie G, Capovilla A, et al. (2009) Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 23: 461–469.
25. Lingappa JR, Barton JM, Wald A, Hughes JP, Thomas KK, et al. (2010) Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 375: 824–833.
26. Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, et al. (1998) Clinical efficacy of high-dose aciclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 176: 349–359.
27. Strick LB, Wald A, Celum C (2006) Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 43: 347–356.
28. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, et al. (1989) Development of clinically recognizable genital lesions among women previously identified as having “asymptomatic” herpes simplex virus type 2 infection. Ann Intern Med 110: 882–887.